2.04
-0.01 (-0.49%)
| Previous Close | 2.05 |
| Open | 2.07 |
| Volume | 1,186,819 |
| Avg. Volume (3M) | 2,686,776 |
| Market Cap | 336,422,496 |
| Price / Earnings (TTM) | 4.08 |
| Price / Earnings (Forward) | 7.70 |
| Price / Sales | 1.40 |
| Price / Book | 2.81 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | 28.19% |
| Operating Margin (TTM) | 44.43% |
| Diluted EPS (TTM) | 0.480 |
| Quarterly Revenue Growth (YOY) | 22.80% |
| Quarterly Earnings Growth (YOY) | 70.60% |
| Total Debt/Equity (MRQ) | 32.53% |
| Current Ratio (MRQ) | 1.73 |
| Operating Cash Flow (TTM) | -81.23 M |
| Levered Free Cash Flow (TTM) | -53.07 M |
| Return on Assets (TTM) | 15.87% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | CytomX Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.0 |
| Average | -0.63 |
|
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.83% |
| % Held by Institutions | 47.10% |
| 52 Weeks Range | ||
| Median | 7.00 (243.14%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Oppenheimer | 31 Jul 2025 | 7.00 (243.14%) | Buy | 2.19 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 28 Aug 2025 | Announcement | CytomX Therapeutics to Present at Upcoming September Investor Conferences |
| 13 Aug 2025 | Announcement | CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study |
| 07 Aug 2025 | Announcement | CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update |
| 31 Jul 2025 | Announcement | CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025 |
| 09 Jul 2025 | Announcement | Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |